BioCorRx Announces BICX101 Preclinical Update; ASAM Attendance
ANAHEIM, CA / ACCESSWIRE / April 5, 2017 / BioCorRx Inc. (BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that is has received updated data from preclinical studies for BICX101, a sustained release, injectable naltrexone for the treatment of opioid abuse and alcoholism. The Company is pleased to announce that three different formulations were successful in reaching 28 days of sustained release of naltrexone. The Company also announced that it will have a booth in the exhibit hall at the American Society of Addiction Medicine (ASAM) conference in New Orleans this week. ASAM is the leading addiction medicine professional society in the U.S. representing over 4,300 physicians, clinicians and professionals with a focus on addiction and its treatment.
Brady Granier, CEO, President, and Director, stated, "We are thrilled that we have been able to hit this milestone in vivo for the first time. Thanks to the work of our team and the folks at TheraKine and Covance, we are getting closer to a final product. We still need to fine tune the formulation to maximize performance, but this data is very exciting. Not only have we reached 28 days of release, but we did it with an injection volume of only 1 ml."
Granier added, "In terms of the Pre-IND meeting request with the FDA, we are working with Innovative Science Solutions to get that done as we are eager to meet with the agency. We anticipated the request being submitted this week and we are still working to that end. It could go into next week depending on what finishing touches are needed, if any, after all regulatory experts have had a chance to review and comment on the final application. We will also be at ASAM later this week which we are very excited about as this is one of the best events in the industry. We will be meeting many key opinion leaders and educating countless addiction specialists about our BioCorRx Recovery Program and BICX101. The attendees of ASAM are all potential partners or customers for our products and programs."
BioCorRx Inc. (BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing a new injectable naltrexone technology (BICX101) through a partnership with TheraKine Ltd. The company plans to seek FDA approval for BICX101 and/or its naltrexone implant product(s). For more information on BICX, visit www.BioCorRx.com.
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
Crescendo Communications, LLC
(212) 671-1020 x304
SOURCE: BioCorRx Inc.
Released April 5, 2017